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ABSTRACT: The synthesis of enantiopure 2,6-
disubstituted morpholines was realized through sequential 
ring-opening of two different optically pure oxiranes by a 
tosylamide, under solid-liquid phase transfer catalysis (SL-
PTC) conditions, mono-O-sulfonylation of the resulting  to-
sylamido-2,2’-diol, and cyclization to the morpholine. The  
crucial step, that is the regioselective formation of the 
mono-sulfonate, was controlled by taking advantage of the 
different stereo, electronic, and coordination properties of 
the oxirane derived side chains in the diol backbone. As an 
application of this protocol, a new morpholine-3-
carboxamide was synthesized starting from threonine. 
 
 Regiochemical control is a stimulating and challenging task in 
many synthetic transformations of important compounds, and in 
particular of small molecules. As an evidence of this, several 
reviews have been recently published on the regioselectivity of 
processes such as the manipulation of hydroxy groups in mono-
saccharide derivatives,1 addition reactions to allenes,2 alkenes,3 
and alkynes,4 the transglycosylation of nucleosides,5 the trans-
formations of chiral substrates controlled by a chiral catalyst,6 
cross-coupling reactions carried out in water,7 the Fujiwara-
Moritani coupling,8 the Pd-catalyzed cross-coupling of dihal-
oarenes,9 and the functionalization of heteroaromatics  by met-
al-catalyzed coupling.10 In the present paper, we describe the 
regiocontrolled mono-O-sulfonylation of diols, whose hydroxy 
groups have  minimal steric and electronic differences, and the 
application of this chemistry in an enantiopure morpholine syn-
thesis. The interest for the regio- and stereoselective synthesis 
of optically pure C-substituted morpholines is increasing, due 
to their wide spectrum of biological activity. In particular, 2,6-
disubstituted morpholines have found application in antisense11 
and foldamer chemistry,12 whereas morpholine 3-carboxylic 
acids induce β-conformations when they replace proline units in 
peptide chains.13 Furthermore, morpholine derivatives have 
been used as HIV protease inhibitors,14 anti-inflammatory15 and 
antimicrobial agents,16 as therapeutics in the treatment of diabe-
tes and obesity,17 mental disorders,18 sexual dysfunctions,19 and 
tumors,20 and as inhibitors of both tumor necrosis factor-α21 and 
matrix metalloproteinases.22 
Scheme 1. Synthesis of 2,6-Disubstituted Morpholines 3: 
Direct Regioselective Protocol (a) vs Protec-
tion/Deprotection Protocol (b). 
 
We previously reported a method for the synthesis of 2,6-
disubstituted morpholines 3 (Scheme 1, path b)23 by intramo-
lecular cyclization of the tosylamidodiol-mono-sulfonate 2. The 
latter was prepared through ring opening reaction of an oxirane 
under solid-liquid phase transfer catalysis (SL-PTC) condi-
tions,24 followed by protection of the hydroxy function of the 
tosylamido alcohol 4 as the THP derivative 5. Then, the reac-
tion with a different oxirane, activation of the new formed hy-
droxy function as an O-tosylate (6→7) and final removal of the 
protective group afforded the desired intermediate 2. Although 
this multistep protocol gives access to a variety of unsymmetric 
morpholines, it suffers from the need of additional protec-
tion/deprotection steps, which negatively influences yields and 
purification operations. Here we report that the same approach 
to 2,6-disubstituted morpholines can be greatly improved by 
avoiding the protection/deprotection steps, through the direct 
and regioselective mono-O-sulfonylation of tosylamidodiols 1 
(Scheme 1, path a).25 This reaction was realized on the diol 1 
via the oxy-dianion formed in situ (Scheme 2, step a). The ap-
proach takes advantage of different features such as i) the steric 
hindrance difference between the carbon atoms bearing OH’s, 
ii) the formation of a more stable sulfonate, and iii) the stabili-
zation of the intermediate sodium alcoholate through extra-
coordination by the side-arm. The tosylamidodiol 1a was cho-
sen as a model compound to investigate the influence on the 
regioselectivity of both the steric hindrance and the intramolec-
ular nucleophilic ring-closing mechanism (Scheme 2). The O-
sulfonylation of the 1a oxydianion with various sulfonylating 
agents (TrisCl, TsCl, and MsCl) at -80 °C produced mixtures of 
the mono-sulfonate 2a and (2R,6S)-2-ethyl-6-phenyl-4-
tosylmorpholine (3a), deriving from the sulfonylation of the 
benzylic oxyanion, followed by rapid cyclization (Table 1). The 
product ratio depends upon the difference in steric hindrance 
around the hydroxy groups and on the size of the R3SO2Cl. 
TrisCl, the largest reagent, preferentially reacted with the less 
hindered hydroxyl on the carbon atom bearing the ethyl group, 
giving good yields of 2a-Tris and minor amounts of enanti-
opure morpholine 3a. 
Scheme 2. Regioselective O-Sulfonylation: SN1 vs SN2 Mech-
anism. 
 
  Table 1. Regioselective Sulfonylation of Tosylami-
dodiol 1a.a 
a Reaction conditions: 1a (1 mmol), R3SO2Cl (1.1 mmol), NaH 
(2.1 mmol), THF (2.5 mL). The dianion was generated by reac-
tion of  1a with NaH at 0 °C for 30 min. b Isolated yields. c 
Morpholine 3a or ent-3a ee’s, determined by chiral HPLC 
analysis. 
The enantiospecific cyclization to 3a  most probably proceeds 
though a pseudo-bimolecular mechanism, with inversion of the 
stereogenic benzylic centre  (Scheme 2). The smaller TsCl and 
MsCl gave different product distributions: the less the steric 
hindrance of the sulfonylating agent the lower the ratio 2a/3a 
(entries 1,2,5). The reaction temperature was a crucial parame-
ter too. Thus, the tosylation of 1a at -65 °C was less regioselec-
tive (entry 3) and, besides, the ee value of the  morpholine 3a 
dropped to 65%, due to the parallel  in situ cyclization of the 
thermodynamic favored 2a-Ts to the enantiomeric morpholine 
ent-3a. This  ring-closing side-reaction became the main pro-
cess at 25 °C (entry 4) and the morpholines were the sole prod-
ucts isolated, ent-3a being the more abundant enantiomer (er 
62:38). 
All the intermediates 2a were cyclized to enantiopure morpho-
line 3a in good yields (9093%) under SL-PTC in acetonitrile, 
by using anhydrous Cs2O3  as base, in the presence of a catalyt-
ic amount of benzyltriethylammonium chloride (TEBA) as 
phase transfer agent (see Scheme 5 and Supporting Infor-
mation). The effect of coordination on regioselectivity has been 
proven by direct O-tosylation26 of the phenylglycidyl ether de-
rived tosylamidodiols 1b,c (Scheme 3), which gave only the 
regioisomers 2b and 2c in 89% and 91% yield, respectively. 
These results can be explained by assuming that two different 
types of ion-pair are present in the intermediate dianions: a 
poorly nucleophilic ‘tight ion-pair’ near the alkyl (or aryl) 
group and a more reactive ‘loose ion-pair’, formed through co-
ordination of the sodium cation by the glycidyl oxygen atom on 
the other side arm. 
Scheme 3. Regioselective O-Sulfonylation: Coordination Ef-
fect. 
 
The tosylation  regioselectivity of diol 1d (Scheme 4), which 
contains the glycidyl derived phenoxy and benzyloxy groups on 
the side chains, is clearly influenced by the inductive effects of 
these groups. Whereas both the sodium cations are coordinated 
by the ether oxygen atoms, the aliphatic benzyl group, through 
its (+I) effect along the σ bonds, increases the charge of the 
near oxyanion, which forms a more tight and then less nucleo-
philic ion-pair with the sodium cation. As a result, even though 
the regioselectivity was not complete, the tosylate derivative 2d 
was the major product.  
Scheme 4. Regioselective O-Sulfonylation: (+I) vs (-I) Effect 
in the Glycidyl Derivative 1d. 
  
Sulfonylation of  the N-tosylamidodiols 1e,f (Table 2) provided 
further confirmation that the higher the difference in the induc-
tive effect between the side chains in diols, the higher the regi-
oselectivity. Thus, the hydroxy group in the C-2 position, adja-
cent to an aryloxymethyl group bearing the strong electron-
withdrawing nitro function, was readily tosylated under the op-
timized reaction conditions to give compounds  2e,f, which 
were isolated in good yield, together with minor amounts of the 
regioisomers reg-2e,f (entries 13).  
Table 2. Regioselective O-Sulfonylation: (+I) vs (-I) Effect in 
Glycidyl Derivatives 1e,f.
a
 
 
entry substrate X R3SO2Cl yield (%) 
1 1e  H TsCl 2e (73) reg-2e (20) 
2 1f  OMe TsCl 2f (78) reg-2f (17) 
3  1fb OMe TsCl 2f (79) reg-2f (17) 
4  1fc OMe TsCl 2f (37) reg-2f (34) 
5  1fd OMe TsCl 2f (41) reg-2f (38) 
6 1f  OMe TrisCl 2g (90)  
a Reaction conditions: 1 (1 mmol), R3SO2Cl (1.1 mmol), NaH 
(2.1 mmol), THF (2.5 mL), at -80 °C, 1 h. b  In 20 mL of THF. c 
In the presence of LiClO4 (8 mmol), at 0 °C, 8 h. 
d In DMF (2.5 
mL).  
Loss of regioselectivity was found by performing the tosylation 
of 1f in the presence of LiClO4 (entry 4), which formed ‘tight  
ion-pairs’ with both the oxyanions, smoothing their relative re-
entry R3SO2Cl 
temp 
(°C) 
time 
(h) 
yield (%)b ee (%)c 
1 TrisCl -80 1.25 2a-Tris (72) 3a (19) 98 
2 TsCl -80 2.5 2a-Ts (57) 3a (25) 80 
3 TsCl -65 72 2a-Ts (42) 3a (52) 65 
4 TsCl 25 6  ent-3a (80) 25 
5 MsCl -80 4.5 2a-Ms (49) 3a (31) 65 
 activity. The same result was reached in the aprotic dipolar 
DMF as solvent (entry 5), which solvated both the sodium al-
coholates generating two ‘solvent separated ion-pairs’ that had 
similar enhanced reactivity, i.e. by taking advantage of the op-
posite effect exerted by the lithium cation. Finally, the reaction 
of 1f with TrisCl (entry 6) gave exclusively 2g. The mono-O-
sulfonylated derivatives 2 and reg-2 were cyclized under SL-
PTC conditions to the corresponding enantiopure morpholines 
3 and ent-3, respectively, in yields up to 95% (Scheme 5).25  
The overall process was successfully applied to the synthesis of 
the new morpholine-3-carboxylic acid derivative 12 starting 
from L-threonine. Regioselective tosylation of the diol 9 as pre-
viously described, gave the sole regioisomer 10 (Scheme 6) 
which, in turn, was SL-PTC cyclized. The resulting N-tosyl 
morpholine 11 was detosylated to 12 by treatment with 40% 
HBr-AcOH, in the presence of phenol.  
In summary, we have described a rapid and efficient regioselec-
tive mono-O-sulfonylation of oxa-dianions derived from non-
symmetric 3-tosylamido-1,5-diols. This selective reactivity,
which to the best of our knowledge is unexplored, depends on 
both the stability and the nucleophilicity of the oxa-dianion ion-
pairs: the combination of steric hindrance and electrodonating 
effects generate a reactive “loose ion-pair” that is preferentially 
tosylated. The 5-hydroxy-sulfonates prepared through the re-
ported procedure are key intermediates for the direct synthesis 
of enantiopure polysubstituted morpholines, such as 12, that 
can be used for the preparation of anti-HBV agents.27 
Scheme 5. Stereoselective Cyclization of mono-Tosylated 
Compounds to Morpholines, Under Solid-Liquid PTC Con-
ditions. 
 
 
Scheme 6. Example of Regioselective O-Tosylation Applied to the Synthesis of 2,6-Disubstitued Morpholine-3-Carboxylic Acid De-
rivative 12. 
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